Ayyobi Amir F, Brunzell John D
Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington 98195, USA.
Am J Cardiol. 2003 Aug 18;92(4A):27J-33J. doi: 10.1016/s0002-9149(03)00613-1.
Metabolic abnormalities associated with the metabolic syndrome are also present in patients with type 2 diabetes mellitus and in those with familial combined hyperlipidemia (FCHL). These abnormalities include central obesity, insulin resistance with hyperinsulinemia, hypertension, increased plasma triglycerides, and decreased high-density lipoprotein cholesterol levels. Other characteristics associated with FCHL include the presence of small, dense low-density lipoprotein cholesterol and increased apolipoprotein B. Patients with these abnormalities are at an increased risk for premature coronary artery disease. Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities.
2型糖尿病患者以及家族性混合型高脂血症（FCHL）患者也存在与代谢综合征相关的代谢异常。这些异常包括中心性肥胖、伴有高胰岛素血症的胰岛素抵抗、高血压、血浆甘油三酯升高以及高密度脂蛋白胆固醇水平降低。与FCHL相关的其他特征包括存在小而密的低密度脂蛋白胆固醇以及载脂蛋白B升高。有这些异常的患者患早发性冠状动脉疾病的风险增加。使用他汀类药物与噻唑烷二酮类药物或烟酸联合治疗与2型糖尿病和FCHL相关的血脂异常，是纠正各种脂质异常的最全面方法。
